Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000637014 | SCV000758462 | likely benign | Cranioectodermal dysplasia 1 | 2023-09-28 | criteria provided, single submitter | clinical testing | |
Gene |
RCV001756057 | SCV001997100 | uncertain significance | not provided | 2019-12-17 | criteria provided, single submitter | clinical testing | In silico analysis, which includes protein predictors and evolutionary conservation, supports a deleterious effect; Has not been previously published as pathogenic or benign to our knowledge |
Fulgent Genetics, |
RCV000637014 | SCV002814503 | uncertain significance | Cranioectodermal dysplasia 1 | 2022-02-19 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004025487 | SCV004885903 | uncertain significance | Inborn genetic diseases | 2021-10-12 | criteria provided, single submitter | clinical testing | The c.1405G>A (p.D469N) alteration is located in exon 13 (coding exon 13) of the IFT122 gene. This alteration results from a G to A substitution at nucleotide position 1405, causing the aspartic acid (D) at amino acid position 469 to be replaced by an asparagine (N). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |